Drug Trial Radar · NCT07907653
Deutenzalutamide and Hormone Therapy Before and After Surgery With Docetaxel Before Surgery for High-Risk Localized or Locally Advanced Prostate Cancer
Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
37
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Jul 2029
Study completion Jan 2035
Sponsor
- Lead sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Hinova Pharmaceuticals Inc.
- First posted
- Oct 30, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the effects and safety of deutenzalutamide combined with hormone therapy before and after prostate cancer surgery, with docetaxel chemotherapy added before surgery. It is intended for men with high-risk localized or locally advanced prostate cancer who have no distant spread on imaging and are suitable for surgery. The researchers will measure how often treatment leaves no cancer or only a very small amount of cancer in the prostate, with no cancer in the pelvic lymph nodes removed during surgery. They will also assess whether participants can undergo the planned surgery, what side effects occur, and whether the cancer returns or spreads during follow-up. Up to 37 participants will be enrolled at several hospitals. All participants will be assigned to the same treatment plan; there is no comparison group. The planned treatment includes: * Deutenzalutamide taken by mouth each day, together with hormone therapy to lower testosterone levels, for 24 weeks before surgery. * Docetaxel given through a vein once every 3 weeks for six cycles during the treatment period before surgery. * Surgery to remove the prostate and pelvic lymph nodes, when medically appropriate. * A further 24 weeks of deutenzalutamide and hormone therapy after recovery from surgery, without further docetaxel. Hormone therapy will continue across the treatment periods for a total of at least 13 months. Treatment may be adjusted or stopped according to side effects and the participant's condition. Follow-up is planned for up to 5 years after all study treatment has ended. Participants may also choose to join an optional study using a single blood sample collected before treatment and leftover tissue from their diagnostic prostate biopsy. These samples will be used to explore features that may be associated with treatment response and later outcomes. Participation in this optional component is not required to receive the study treatment.
Conditions
- Prostate Cancer (Adenocarcinoma)
Interventions
DeutenzalutamideDrug
Deutenzalutamide 80 mg is administered orally once daily with androgen deprivation therapy (ADT) for 24 weeks before radical prostatectomy. After adequate postoperative recovery, deutenzalutamide is planned to resume approximately 4 weeks after surgery at the last tolerated dose, with ADT, for an additional 24 weeks. Dose modifications and treatment interruptions are managed according to the protocol.
DocetaxelDrug
Docetaxel 60 mg/m² is administered by intravenous infusion every 3 weeks for 6 cycles (planned at Weeks 0, 3, 6, 9, 12, and 15) during neoadjuvant treatment, in combination with deutenzalutamide and androgen deprivation therapy (ADT). Treatment interruptions and discontinuation follow protocol-defined criteria; docetaxel is not administered during postoperative adjuvant treatment.
ADTDrug
Androgen deprivation therapy (ADT) is administered according to the prescribing information for the selected agent. Treatment begins in the neoadjuvant phase and continues through the perioperative and postoperative adjuvant phases for a total duration of at least 13 months.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pathological Complete Response or Minimal Residual Disease (pCR/MRD) RateTime frame: At postoperative pathological assessment (surgery planned approximately 26 weeks after treatment initiation; qualifying surgery within 56 days after the actual end of neoadjuvant treatment).
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.